BioNTech Investor Day Presentation Deck

Mutations from cancer tissues are druggable and 15-20% of mutations are immunogenic when exploited as vaccine targets Exploiting the Mutanome for Tumor Vaccination John C. Castle¹, Sebastian Kreiter¹, Jan Diekmann¹, Martin Löwer¹, Niels van de Roemer¹,2, Jos de Graaf¹, Abderraouf Selmi¹, Mustafa Diken¹, Sebastian Boegel¹2, Claudia Paret¹, Michael Koslowski¹, Andreas N. Kuhn ¹,3, Cedrik M. Britten2,3, Christoph Huber¹,3, Özlem Türeci, and Ugur Sahin ¹,2,3 C57BL/6 (DNA) Castle JC, et al. Cancer Res 2012; 72:1081-1091. Mutation discovery B16F10 DNA and RNA Immunogenicity testing DNA and RNA sequencing Cancer Research шипники Validated mutations Sequence analysis Normal Tumor Mutation identification Immunize with peptide containing mutation Mutation validation ELISPOT mutated and wild type Target discovery BIONTECH 19

View entire presentation